790305-00-9

Basic information

• Product Name: (S)-2-(tert-butoxycarbonylamino)-3-(pent-4-enyloxy)propanoic acid
• Synonyms: (S)-2-(tert-butoxycarbonylamino)-3-(pent-4-enyloxy)propanoic acid;(S)-2-((tert-Butoxycarbonyl)aMino)-3-(pent-4-en-1-yloxy)propanoic acid
• CAS NO: 790305-00-9
• Molecular Formula: C₁₃H₂₃NO₅
• Molecular Weight: 273.32542
• Mol File: 790305-00-9.mol

Chemical Properties

• Boiling Point: 412.9±45.0 °C(Predicted)
• Appearance: /
• Density: 1.084±0.06 g/cm3(Predicted)
• Storage Temp.: 2-8°C
• PKA: 3.54±0.10(Predicted)
• CAS DataBase Reference: (S)-2-(tert-butoxycarbonylamino)-3-(pent-4-enyloxy)propanoic acid(CAS DataBase Reference)
• NIST Chemistry Reference: (S)-2-(tert-butoxycarbonylamino)-3-(pent-4-enyloxy)propanoic acid(790305-00-9)
• EPA Substance Registry System: (S)-2-(tert-butoxycarbonylamino)-3-(pent-4-enyloxy)propanoic acid(790305-00-9)

Safety Data

• Hazardous Substances Data: 790305-00-9(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
(S)-2-(tert-butoxycarbonylamino)-3-(pent-4-enyloxy)propanoic acid is used as a pharmaceutical intermediate for the development of new drugs, leveraging its anti-inflammatory and analgesic properties inherent to propanoic acids.
Used in Peptide Synthesis:
In the field of organic chemistry, (S)-2-(tert-butoxycarbonylamino)-3-(pent-4-enyloxy)propanoic acid serves as a building block in peptide synthesis, where the boc-protected amino group is crucial for the stepwise assembly of peptide chains.
Used in Drug Delivery Systems:
(S)-2-(tert-butoxycarbonylamino)-3-(pent-4-enyloxy)propanoic acid is utilized in the design of drug delivery systems to improve the bioavailability and targeting of therapeutic agents, taking advantage of its structural features to enhance drug efficacy and reduce side effects.

Upstream product

• 3262-72-4 (S)-N-(tert-butoxycarbonyl)serine 
• 1119-51-3 bromopentene 
• 2766-43-0 N-tert-butyloxycarbonyl-L-serine methyl ester 
• 790304-99-3 2-tert-butoxycarbonylamino-3-pent-4-enyloxypropionic acid methyl ester 

Downstream Products

• 790304-99-3 2-tert-butoxycarbonylamino-3-pent-4-enyloxypropionic acid methyl ester 
• 1338650-05-7 1-{[4-(4-bromobenzenesulfonyloxy)-1-(2-cyclopentyloxycarbonylamino-3-pent-4-enyloxypropionyl)pyrrolidine-2-carbonyl]amino}-2-vinylcyclopropanecarboxylic acid ethyl ester 

Relevant articles and documents

Water-soluble poly(l -serine)s with elongated and charged side-chains: Synthesis, conformations, and cell-penetrating properties

Water-soluble poly(l-serine)s bearing long side-chain with terminal charge groups were synthesized via ring-opening polymerization of O-pentenyl-l-serine N-carboxyanhydride followed by thiol-ene reactions. These side-chain modified poly(l-serine)s adopt β

Genetically encoded alkenes in yeast

(Figure Presented) Olefin-containing amino acids have been genetically introduced into proteins in Saccharomyces cerevisiae by orthogonal tRNA/aminoacyl-tRNA synthetase pairs. These nonnatural amino acids can be used for selective protein modification thr

Stable helical ionic polypeptides

The invention provides polymers comprising Formula I: wherein monomer is a repeating unit comprising 2, 3, 4, 5, 6 or 7 carbon atoms and the monomers are linked together through amide or ester bonds; n is about 6 to about 1000; and Linker is an optionally

A concise synthesis of the HCV protease inhibitor BILN 2061 and its P3 modified analogs

A concise synthesis of BILN 2061 was achieved through more efficient installation of P2 4-quinoline moiety via SN2 displacement of the β-OBs group located on the 4-hydroxyl proline intermediate, which was prepared from 4-α-hydroxyl proline analog via Mitsunobu reaction with inversion of stereochemistry. In addition, a short and practical synthesis for P3 unit is also described herein. Final assembly of four fragments for BILN 2061 was achieved with an overall yield of 58% in 4 steps from P1 to 15a. Furthermore several analogs of BILN 2061 (WX-1-WX-5) containing modifications on P3 unit were synthesized successfully using the same synthetic route as described for the parent inhibitor BILN 2061. Copyright

Inhibitors of Hepatitis C Virus

Macrocyclic peptides are disclosed having the general formula: wherein R3, R3′, R4, R6, R′, X, Q and W are described. Compositions comprising the compounds and methods for using the compounds to inhibit HCV are also disclosed.

MACROCYCLIC PEPTIDES AS HEPATITIS C VIRUS INHIBITORS

Macrocyclic peptides having the general formula (I): are disclosed. Compositions comprising the compounds and methods for using the compounds to inhibit HCV are also disclosed.

Inhibitors of Hepatitis C Virus

Macrocyclic peptides are disclosed having the general formula: wherein R3, R3′, R4, R6, R′, X, Q and W are described. Compositions comprising the compounds and methods for using the compounds to inhibit HCV are also disclosed.

Inhibitors of Hepatitis C Virus

Macrocyclic peptides are disclosed having the general formula: wherein R3, R′3, R4, R6, R′, X, Q and W are described. Compositions comprising the compounds and methods for using the compounds to inhibit HCV are also disclosed.

MACROCYCLIC PEPTIDES AS HEPATITIS C VIRUS INHIBITORS

Macrocyclic peptides having the general formula are disclosed. Compositions comprising the compounds and methods for using the compounds to inhibit HCV are also disclosed.

Hepatitis C virus inhibitors

Hepatitis C virus inhibitors having the general formula are disclosed. Compositions comprising the compounds and methods for using the compounds to inhibit HCV are also disclosed.